PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
AcelRx Pharmaceuticals, Inc. (ACRX)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS00444T1007
CUSIP00444T100
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

Highlights

Market Cap$14.58M
EPS (TTM)-$2.75
PE Ratio0.13
Total Revenue (TTM)$651.00K
Gross Profit (TTM)-$1.18M
EBITDA (TTM)-$5.34M
Year Range$0.43 - $1.61
Target Price$4.63
Short %3.75%
Short Ratio4.56

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


AcelRx Pharmaceuticals, Inc.

Popular comparisons: ACRX vs. SCHG

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in AcelRx Pharmaceuticals, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%0.00%100.00%200.00%300.00%Dec 17Dec 24Dec 31Jan 07Jan 14Jan 21Jan 28Feb 04Feb 11Feb 18Feb 25Mar 03Mar 10
-98.76%
289.37%
ACRX (AcelRx Pharmaceuticals, Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period


PeriodReturnBenchmark
Year-To-DateN/A13.87%
1 monthN/A2.33%
6 monthsN/A15.10%
1 yearN/A22.72%
5 years (annualized)N/A13.49%
10 years (annualized)N/A10.85%

Monthly Returns

The table below presents the monthly returns of ACRX, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202440.54%30.77%52.39%
2023-11.50%-29.00%-53.66%1.82%48.66%11.45%-7.21%-0.00%-43.69%-10.34%42.31%0.00%-67.26%
2022-14.21%-6.05%-36.77%-12.54%-9.05%7.57%-15.68%43.20%-29.15%-36.84%-9.47%-5.44%-79.83%
202177.42%-14.55%-9.57%-23.53%6.92%-0.72%-14.49%-5.08%-8.93%-13.73%-25.93%-14.05%-54.82%
2020-19.43%-22.35%-10.61%36.44%-13.66%-12.95%-9.92%14.68%13.60%20.42%-12.28%-17.33%-41.23%
20196.49%36.59%3.57%11.21%-33.07%-2.32%3.16%-10.73%-5.58%-9.09%-7.00%13.44%-8.66%
2018-6.17%-5.26%16.67%14.29%41.67%-0.74%-17.04%10.71%24.19%7.53%-18.60%-31.45%14.07%
20171.92%15.09%3.28%-17.46%-3.85%-14.00%81.40%-15.38%39.39%-58.70%14.47%-6.90%-22.12%
2016-6.23%2.77%-16.98%9.74%2.37%-22.25%34.94%-13.22%23.49%-28.02%10.71%-16.13%-32.47%
2015-0.45%32.24%-56.43%3.37%-12.28%21.14%-2.83%3.88%-28.74%29.18%45.18%-32.69%-42.79%
20140.97%0.09%5.07%-9.91%-14.97%11.41%-32.10%2.73%-23.22%20.77%0.45%1.05%-40.50%
201326.06%-6.89%3.20%13.57%52.05%4.04%25.67%-14.94%8.78%-37.66%45.54%15.64%165.49%

Risk-Adjusted Performance

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for AcelRx Pharmaceuticals, Inc. (ACRX) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


ACRX
Sharpe ratio
No data
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 2.14, compared to the broader market-2.00-1.000.001.002.003.002.14
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 3.04, compared to the broader market-4.00-2.000.002.004.006.003.04
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.38, compared to the broader market0.501.001.502.001.38
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.71, compared to the broader market0.002.004.006.001.71
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 8.02, compared to the broader market-10.000.0010.0020.008.02

Sharpe Ratio

There is not enough data available to calculate the Sharpe ratio for AcelRx Pharmaceuticals, Inc.. We calculate this metric based on the past 12 months of trading data. Please check back later for updated information.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00Dec 17Dec 24Dec 31Jan 07Jan 14Jan 21Jan 28Feb 04Feb 11Feb 18Feb 25Mar 03Mar 10
-0.04
2.84
ACRX (AcelRx Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


AcelRx Pharmaceuticals, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%Dec 17Dec 24Dec 31Jan 07Jan 14Jan 21Jan 28Feb 04Feb 11Feb 18Feb 25Mar 03Mar 10
-99.57%
0
ACRX (AcelRx Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the AcelRx Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the AcelRx Pharmaceuticals, Inc. was 99.82%, occurring on Nov 10, 2023. The portfolio has not yet recovered.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.82%Jul 23, 20132595Nov 10, 2023
-60%Jun 1, 2011135Dec 30, 2011218Nov 26, 2012353
-33.63%Feb 14, 201146Apr 19, 201127May 27, 201173
-33.4%Nov 27, 20128Dec 6, 201229Jan 18, 201337
-21.97%Feb 14, 201323Mar 19, 201316Apr 11, 201339

Volatility

Volatility Chart

The current AcelRx Pharmaceuticals, Inc. volatility is 34.32%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%50.00%Dec 17Dec 24Dec 31Jan 07Jan 14Jan 21Jan 28Feb 04Feb 11Feb 18Feb 25Mar 03Mar 10
34.32%
3.68%
ACRX (AcelRx Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of AcelRx Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items